Epicrispr Biotechnologies
$68.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Epicrispr Biotechnologies is currently valued at N/A as of March 26, 2025. The company has raised a total of $123.0M in funding.
Investment Perspective
Epicrispr Biotechnologies's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Epicrispr Biotechnologies Worth in 2025?
As of 2025, Epicrispr Biotechnologies is valued at N/A, based on the company's Later Stage VC funding round in March 26, 2025. This valuation positions Epicrispr Biotechnologies as one of the leading private companies in the sector.
Epicrispr Biotechnologies Valuation History
Epicrispr Biotechnologies's funding history demonstrates steady growth and investor confidence.
How Epicrispr Biotechnologies Valuation is Determined
Private company valuations like Epicrispr Biotechnologies's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Epicrispr Biotechnologies Valuation FAQs
Is Epicrispr Biotechnologies profitable?
Epicrispr Biotechnologies has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Epicrispr Biotechnologies's valuation compare to competitors?
Epicrispr Biotechnologies is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Epicrispr Biotechnologies IPO?
Epicrispr Biotechnologies has not announced plans for an initial public offering. Until an IPO, investors can access Epicrispr Biotechnologies shares through secondary market platforms.